Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 157

1.

Utilization and determinants of follow-up colonoscopies within 6 years after screening colonoscopy: prospective cohort study.

Hoffmeister M, Holleczek B, Stock C, Zwink N, Stolz T, Stegmaier C, Brenner H.

Int J Cancer. 2018 Sep 11. doi: 10.1002/ijc.31862. [Epub ahead of print]

PMID:
30203838
2.

Prediction of myocardial infarction, stroke and cardiovascular mortality with urinary biomarkers of oxidative stress: Results from a large cohort study.

Xuan Y, Gào X, Holleczek B, Brenner H, Schöttker B.

Int J Cardiol. 2018 Aug 3. pii: S0167-5273(18)33360-6. doi: 10.1016/j.ijcard.2018.08.002. [Epub ahead of print]

PMID:
30100224
3.

Long-term relative survival from melanoma in Germany 1997-2013.

Brunssen A, Jansen L, Eisemann N, Waldmann A, Weberpals J, Kraywinkel K, Eberle A, Holleczek B, Zeissig SR, Brenner H, Katalinic A; GEKID Cancer Survival Working Group.

Melanoma Res. 2018 Jul 16. doi: 10.1097/CMR.0000000000000482. [Epub ahead of print]

PMID:
30020195
4.

The role of psychosocial resources for long-term breast, colorectal, and prostate cancer survivors: prevalence and associations with health-related quality of life.

Doege D, Thong M, Koch-Gallenkamp L, Bertram H, Eberle A, Holleczek B, Waldeyer-Sauerland M, Waldmann A, Zeissig SR, Brenner H, Arndt V.

Support Care Cancer. 2018 Jun 27. doi: 10.1007/s00520-018-4317-8. [Epub ahead of print]

PMID:
29951713
5.

Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants.

Dadaev T, Saunders EJ, Newcombe PJ, Anokian E, Leongamornlert DA, Brook MN, Cieza-Borrella C, Mijuskovic M, Wakerell S, Olama AAA, Schumacher FR, Berndt SI, Benlloch S, Ahmed M, Goh C, Sheng X, Zhang Z, Muir K, Govindasami K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman P, Thompson IM Jr, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger G, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Hakansson N, West C, Dunning AM, Burnet N, Mucci L, Giovannucci E, Andriole G, Cussenot O, Cancel-Tassin G, Koutros S, Freeman LEB, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein B, Kerns S, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Fachal L, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weisher M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Slavov C, Mitev V, Parliament M, Singhal S, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Gago-Dominguez M, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Kierzek A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Kraft P; PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium, Freedman M, Wiklund F, Chanock S, Henderson BE, Easton DF, Haiman CA, Eeles RA, Conti DV, Kote-Jarai Z.

Nat Commun. 2018 Jun 11;9(1):2256. doi: 10.1038/s41467-018-04109-8.

6.

Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.

Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, Dadaev T, Leongamornlert D, Anokian E, Cieza-Borrella C, Goh C, Brook MN, Sheng X, Fachal L, Dennis J, Tyrer J, Muir K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman PJ, Thompson IM Jr, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger GP, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Håkansson N, West CML, Dunning AM, Burnet N, Mucci LA, Giovannucci E, Andriole GL, Cussenot O, Cancel-Tassin G, Koutros S, Beane Freeman LE, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein BS, Kerns SL, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weischer M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Singhal S, Slavov C, Mitev V, Parliament M, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Dominguez MG, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA; Profile Study, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Cui Z, Kraft P; Australian Prostate Cancer BioResource (APCB); IMPACT Study; Canary PASS Investigators; Breast and Prostate Cancer Cohort Consortium (BPC3); PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium; Cancer of the Prostate in Sweden (CAPS); Prostate Cancer Genome-wide Association Study of Uncommon Susceptibility Loci (PEGASUS); Genetic Associations and Mechanisms in Oncology (GAME-ON)/Elucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE) Consortium, Amos CI, Conti DV, Easton DF, Wiklund F, Chanock SJ, Henderson BE, Kote-Jarai Z, Haiman CA, Eeles RA.

Nat Genet. 2018 Jul;50(7):928-936. doi: 10.1038/s41588-018-0142-8. Epub 2018 Jun 11.

PMID:
29892016
7.

Urinary 8-isoprostane levels and occurrence of lung, colorectal, prostate, breast and overall cancer: Results from a large, population-based cohort study with 14 years of follow-up.

Gào X, Brenner H, Holleczek B, Cuk K, Zhang Y, Anusruti A, Xuan Y, Xu Y, Schöttker B.

Free Radic Biol Med. 2018 Aug 1;123:20-26. doi: 10.1016/j.freeradbiomed.2018.05.065. Epub 2018 May 17.

PMID:
29778463
8.

E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium.

Horne HN, Oh H, Sherman ME, Palakal M, Hewitt SM, Schmidt MK, Milne RL, Hardisson D, Benitez J, Blomqvist C, Bolla MK, Brenner H, Chang-Claude J, Cora R, Couch FJ, Cuk K, Devilee P, Easton DF, Eccles DM, Eilber U, Hartikainen JM, Heikkilä P, Holleczek B, Hooning MJ, Jones M, Keeman R, Mannermaa A, Martens JWM, Muranen TA, Nevanlinna H, Olson JE, Orr N, Perez JIA, Pharoah PDP, Ruddy KJ, Saum KU, Schoemaker MJ, Seynaeve C, Sironen R, Smit VTHBM, Swerdlow AJ, Tengström M, Thomas AS, Timmermans AM, Tollenaar RAEM, Troester MA, van Asperen CJ, van Deurzen CHM, Van Leeuwen FF, Van't Veer LJ, García-Closas M, Figueroa JD.

Sci Rep. 2018 Apr 26;8(1):6574. doi: 10.1038/s41598-018-23733-4.

9.

Amyloid blood biomarker detects Alzheimer's disease.

Nabers A, Perna L, Lange J, Mons U, Schartner J, Güldenhaupt J, Saum KU, Janelidze S, Holleczek B, Rujescu D, Hansson O, Gerwert K, Brenner H.

EMBO Mol Med. 2018 May;10(5). pii: e8763. doi: 10.15252/emmm.201708763.

10.

Updated analysis on polypharmacy and mortality from the ESTHER study.

Schöttker B, Muhlack DC, Hoppe LK, Holleczek B, Brenner H.

Eur J Clin Pharmacol. 2018 Jul;74(7):981-982. doi: 10.1007/s00228-018-2445-1. Epub 2018 Apr 6. No abstract available.

PMID:
29623360
11.

Methylomic survival predictors, frailty, and mortality.

Zhang Y, Saum KU, Schöttker B, Holleczek B, Brenner H.

Aging (Albany NY). 2018 Mar 6;10(3):339-357. doi: 10.18632/aging.101392.

12.

Survival of patients with hepatobiliary tract and duodenal cancer sites in Germany and the United States in the early 21st century.

Pulte D, Weberpals J, Schröder CC, Emrich K, Holleczek B, Katalinic A, Luttmann S, Sirri E, Jansen L, Brenner H; GEKID Cancer Survival Working Group.

Int J Cancer. 2018 Jul 15;143(2):324-332. doi: 10.1002/ijc.31322. Epub 2018 Mar 5.

PMID:
29479701
13.

Dietary patterns and risk of advanced colorectal neoplasms: A large population based screening study in Germany.

Erben V, Carr PR, Holleczek B, Stegmaier C, Hoffmeister M, Brenner H.

Prev Med. 2018 Jun;111:101-109. doi: 10.1016/j.ypmed.2018.02.025. Epub 2018 Feb 23.

PMID:
29477967
14.

Stage of cancer diagnoses among migrants from the former Soviet Union in comparison to the German population - are diagnoses among migrants delayed?

Cho AB, Jaehn P, Holleczek B, Becher H, Winkler V.

BMC Public Health. 2018 Jan 17;18(1):148. doi: 10.1186/s12889-018-5046-0.

15.

Differences in incidence and survival of oral cavity and pharyngeal cancers between Germany and the United States depend on the HPV-association of the cancer site.

Jansen L, Buttmann-Schweiger N, Listl S, Ressing M, Holleczek B, Katalinic A, Luttmann S, Kraywinkel K, Brenner H; GEKID Cancer Survival Working Group.

Oral Oncol. 2018 Jan;76:8-15. doi: 10.1016/j.oraloncology.2017.11.015. Epub 2017 Nov 21.

PMID:
29290288
16.

FGFR1 gene amplification in squamous cell carcinomas of the lung: a potential favorable prognostic marker for women and for patients with advanced cancer.

Flockerzi FA, Roggia C, Langer F, Holleczek B, Bohle RM.

Virchows Arch. 2018 May;472(5):759-769. doi: 10.1007/s00428-017-2282-0. Epub 2017 Dec 21.

PMID:
29270870
17.

Burden of hip fracture using disability-adjusted life-years: a pooled analysis of prospective cohorts in the CHANCES consortium.

Papadimitriou N, Tsilidis KK, Orfanos P, Benetou V, Ntzani EE, Soerjomataram I, Künn-Nelen A, Pettersson-Kymmer U, Eriksson S, Brenner H, Schöttker B, Saum KU, Holleczek B, Grodstein FD, Feskanich D, Orsini N, Wolk A, Bellavia A, Wilsgaard T, Jørgensen L, Boffetta P, Trichopoulos D, Trichopoulou A.

Lancet Public Health. 2017 May;2(5):e239-e246. doi: 10.1016/S2468-2667(17)30046-4. Epub 2017 Apr 11.

18.

Body mass index and breast cancer survival: a Mendelian randomization analysis.

Guo Q, Burgess S, Turman C, Bolla MK, Wang Q, Lush M, Abraham J, Aittomäki K, Andrulis IL, Apicella C, Arndt V, Barrdahl M, Benitez J, Berg CD, Blomqvist C, Bojesen SE, Bonanni B, Brand JS, Brenner H, Broeks A, Burwinkel B, Caldas C, Campa D, Canzian F, Chang-Claude J, Chanock SJ, Chin SF, Couch FJ, Cox A, Cross SS, Cybulski C, Czene K, Darabi H, Devilee P, Diver WR, Dunning AM, Earl HM, Eccles DM, Ekici AB, Eriksson M, Evans DG, Fasching PA, Figueroa J, Flesch-Janys D, Flyger H, Gapstur SM, Gaudet MM, Giles GG, Glendon G, Grip M, Gronwald J, Haeberle L, Haiman CA, Hall P, Hamann U, Hankinson S, Hartikainen JM, Hein A, Hiller L, Hogervorst FB, Holleczek B, Hooning MJ, Hoover RN, Humphreys K, Hunter DJ, Hüsing A, Jakubowska A, Jukkola-Vuorinen A, Kaaks R, Kabisch M, Kataja V; kConFab/AOCS Investigators, Knight JA, Koppert LB, Kosma VM, Kristensen VN, Lambrechts D, Le Marchand L, Li J, Lindblom A, Lindström S, Lissowska J, Lubinski J, Machiela MJ, Mannermaa A, Manoukian S, Margolin S, Marme F, Martens JWM, McLean C, Menéndez P, Milne RL, Marie Mulligan A, Muranen TA, Nevanlinna H, Neven P, Nielsen SF, Nordestgaard BG, Olson JE, Perez JIA, Peterlongo P, Phillips KA, Poole CJ, Pylkäs K, Radice P, Rahman N, Rüdiger T, Rudolph A, Sawyer EJ, Schumacher F, Seibold P, Seynaeve C, Shah M, Smeets A, Southey MC, Tollenaar RAEM, Tomlinson I, Tsimiklis H, Ulmer HU, Vachon C, van den Ouweland AMW, Van't Veer LJ, Wildiers H, Willett W, Winqvist R, Zamora MP, Chenevix-Trench G, Dörk T, Easton DF, García-Closas M, Kraft P, Hopper JL, Zheng W, Schmidt MK, Pharoah PDP.

Int J Epidemiol. 2017 Dec 1;46(6):1814-1822. doi: 10.1093/ije/dyx131.

19.

Observed and expected mortality in the German skin cancer screening pilot project SCREEN.

Eisemann N, Waldmann A, Holleczek B, Katalinic A.

J Med Screen. 2018 Sep;25(3):166-168. doi: 10.1177/0969141317734003. Epub 2017 Nov 24.

PMID:
29169295
20.

Response: Methods for second primary cancers evaluation have to be standardized.

Chen T, Brenner H, Fallah M, Jansen L, Castro FA, Geiss K, Holleczek B, Katalinic A, Luttmann S, Sundquist K, Ressing M, Xu L, Hemminki K; GEKID Cancer Survival Working Group.

Int J Cancer. 2018 Mar 15;142(6):1286-1287. doi: 10.1002/ijc.31151. Epub 2017 Nov 24. No abstract available.

PMID:
29134649
21.

Frailty and healthcare costs-longitudinal results of a prospective cohort study.

Hajek A, Bock JO, Saum KU, Matschinger H, Brenner H, Holleczek B, Haefeli WE, Heider D, König HH.

Age Ageing. 2018 Mar 1;47(2):233-241. doi: 10.1093/ageing/afx157.

PMID:
29036424
22.

No Association of Vitamin D Pathway Genetic Variants with Cancer Risks in a Population-Based Cohort of German Older Adults.

Ordóñez-Mena JM, Schöttker B, Saum KU, Holleczek B, Burwinkel B, Wang TJ, Brenner H.

Cancer Epidemiol Biomarkers Prev. 2017 Sep;26(9):1459-1461. doi: 10.1158/1055-9965.EPI-17-0191.

23.

Risk of second primary cancers in women diagnosed with endometrial cancer in German and Swedish cancer registries.

Chen T, Brenner H, Fallah M, Jansen L, Castro FA, Geiss K, Holleczek B, Katalinic A, Luttmann S, Sundquist K, Ressing M, Xu L, Hemminki K; GEKID Cancer Survival Working Group+.

Int J Cancer. 2017 Dec 1;141(11):2270-2280. doi: 10.1002/ijc.30930. Epub 2017 Aug 29.

PMID:
28815572
24.

Survival for patients with rare haematologic malignancies: Changes in the early 21st century.

Pulte D, Weberpals J, Jansen L, Luttmann S, Holleczek B, Nennecke A, Ressing M, Katalinic A, Brenner H; GEKID Cancer Survival Working Group.

Eur J Cancer. 2017 Oct;84:81-87. doi: 10.1016/j.ejca.2017.07.014. Epub 2017 Aug 8.

PMID:
28800491
25.

Vulvar cancer in Germany: increase in incidence and change in tumour biological characteristics from 1974 to 2013.

Holleczek B, Sehouli J, Barinoff J.

Acta Oncol. 2018 Mar;57(3):324-330. doi: 10.1080/0284186X.2017.1360513. Epub 2017 Aug 11.

PMID:
28799431
26.

In Reply.

Hoffmeister M, Holleczek B, Stock C, Brenner H.

Dtsch Arztebl Int. 2017 Jun 23;114(25):427. doi: 10.3238/arztebl.2017.0427. No abstract available.

27.

Toward a comprehensive cancer registration in Germany.

Holleczek B, Katalinic A.

Eur J Cancer Prev. 2017 Sep;26 Joining forces for better cancer registration in Europe:S132-S138. doi: 10.1097/CEJ.0000000000000388.

PMID:
28639952
28.

Complication Rates in Colonoscopy Screening for Cancer.

Zwink N, Holleczek B, Stegmaier C, Hoffmeister M, Brenner H.

Dtsch Arztebl Int. 2017 May 5;114(18):321-327. doi: 10.3238/arztebl.2017.0321.

29.

Polypharmacy and mortality: new insights from a large cohort of older adults by detection of effect modification by multi-morbidity and comprehensive correction of confounding by indication.

Schöttker B, Saum KU, Muhlack DC, Hoppe LK, Holleczek B, Brenner H.

Eur J Clin Pharmacol. 2017 Aug;73(8):1041-1048. doi: 10.1007/s00228-017-2266-7. Epub 2017 May 24.

PMID:
28540438
30.

Vitamin D Supplementation Trials Aimed at Reducing Mortality Have Much Higher Power When Focusing on People with Low Serum 25-Hydroxyvitamin D Concentrations.

Brenner H, Jansen L, Saum KU, Holleczek B, Schöttker B.

J Nutr. 2017 Jul;147(7):1325-1333. doi: 10.3945/jn.117.250191. Epub 2017 May 24.

PMID:
28539415
31.

Incidence, Mortality, and Trends of Nonmelanoma Skin Cancer in Germany.

Leiter U, Keim U, Eigentler T, Katalinic A, Holleczek B, Martus P, Garbe C.

J Invest Dermatol. 2017 Sep;137(9):1860-1867. doi: 10.1016/j.jid.2017.04.020. Epub 2017 May 6.

32.

Meat intake and risk of colorectal polyps: results from a large population-based screening study in Germany.

Carr PR, Holleczek B, Stegmaier C, Brenner H, Hoffmeister M.

Am J Clin Nutr. 2017 Jun;105(6):1453-1461. doi: 10.3945/ajcn.116.148304. Epub 2017 May 3.

PMID:
28468894
33.

Time trends of cause-specific mortality among resettlers in Germany, 1990 through 2009.

Kaucher S, Leier V, Deckert A, Holleczek B, Meisinger C, Winkler V, Becher H.

Eur J Epidemiol. 2017 Apr;32(4):289-298. doi: 10.1007/s10654-017-0240-4. Epub 2017 Mar 17.

PMID:
28314982
34.

DNA methylation signatures in peripheral blood strongly predict all-cause mortality.

Zhang Y, Wilson R, Heiss J, Breitling LP, Saum KU, Schöttker B, Holleczek B, Waldenberger M, Peters A, Brenner H.

Nat Commun. 2017 Mar 17;8:14617. doi: 10.1038/ncomms14617.

35.

Survival of patients with lymphoplasmacytic lymphoma and solitary plasmacytoma in Germany and the United States of America in the early 21st century.

Weberpals J, Pulte D, Jansen L, Luttmann S, Holleczek B, Nennecke A, Ressing M, Katalinic A, Merz M, Brenner H; GEKID Cancer Survival Working Group.

Haematologica. 2017 Jun;102(6):e229-e232. doi: 10.3324/haematol.2016.157768. Epub 2017 Mar 9. No abstract available.

36.

Screening for Bowel Cancer: Increasing Participation via Personal Invitation.

Hoffmeister M, Holleczek B, Zwink N, Stock C, Stegmaier C, Brenner H.

Dtsch Arztebl Int. 2017 Feb 10;114(6):87-93. doi: 10.3238/arztebl.2017.0087.

37.

TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer.

Fagerholm R, Khan S, Schmidt MK, García-Closas M, Heikkilä P, Saarela J, Beesley J, Jamshidi M, Aittomäki K, Liu J, Ali HR, Andrulis IL, Beckmann MW, Behrens S, Blows FM, Brenner H, Chang-Claude J, Couch FJ, Czene K, Fasching PA, Figueroa J, Floris G, Glendon G, Guo Q, Hall P, Hallberg E, Hamann U, Holleczek B, Hooning MJ, Hopper JL, Jager A, Kabisch M; kConFab/AOCS Investigators, Keeman R, Kosma VM, Lambrechts D, Lindblom A, Mannermaa A, Margolin S, Provenzano E, Shah M, Southey MC, Dennis J, Lush M, Michailidou K, Wang Q, Bolla MK, Dunning AM, Easton DF, Pharoah PD, Chenevix-Trench G, Blomqvist C, Nevanlinna H.

Oncotarget. 2017 Mar 14;8(11):18381-18398. doi: 10.18632/oncotarget.15110.

38.

Incidence of lip malignancies in Germany-data from nine population-based cancer registries.

Singer S, Zeissig SR, Emrich K, Holleczek B, Kraywinkel K, Ressing M.

J Oral Pathol Med. 2017 Oct;46(9):780-785. doi: 10.1111/jop.12559. Epub 2017 Mar 2.

PMID:
28178758
39.

Quality of life in long-term and very long-term cancer survivors versus population controls in Germany.

Arndt V, Koch-Gallenkamp L, Jansen L, Bertram H, Eberle A, Holleczek B, Schmid-Höpfner S, Waldmann A, Zeissig SR, Brenner H.

Acta Oncol. 2017 Feb;56(2):190-197. doi: 10.1080/0284186X.2016.1266089. Epub 2017 Jan 5.

PMID:
28055266
40.

Is Polypharmacy Associated with Frailty in Older People? Results From the ESTHER Cohort Study.

Saum KU, Schöttker B, Meid AD, Holleczek B, Haefeli WE, Hauer K, Brenner H.

J Am Geriatr Soc. 2017 Feb;65(2):e27-e32. doi: 10.1111/jgs.14718. Epub 2016 Dec 26.

PMID:
28024089
41.

Smoking-associated DNA methylation markers predict lung cancer incidence.

Zhang Y, Elgizouli M, Schöttker B, Holleczek B, Nieters A, Brenner H.

Clin Epigenetics. 2016 Nov 25;8:127. doi: 10.1186/s13148-016-0292-4. eCollection 2016.

42.

Genetic Variants in the Vitamin D Pathway, 25(OH)D Levels, and Mortality in a Large Population-Based Cohort Study.

Ordóñez-Mena JM, Maalmi H, Schöttker B, Saum KU, Holleczek B, Wang TJ, Burwinkel B, Brenner H.

J Clin Endocrinol Metab. 2017 Feb 1;102(2):470-477. doi: 10.1210/jc.2016-2468.

PMID:
27732326
43.

Pneumonia in the Noninstitutionalized Older Population.

Breitling LP, Saum KU, Schöttker B, Holleczek B, Herth FJ, Brenner H.

Dtsch Arztebl Int. 2016 Sep 16;113(37):607-614. doi: 10.3238/arztebl.2016.0607.

44.

In Reply.

Brenner H, Schrotz-King P, Hoffmeister M, Holleczek B, Katalinic A.

Dtsch Arztebl Int. 2016 Jul 25;113(29-30):507-8. doi: 10.3238/arztebl.2016.0507b. No abstract available.

45.

Comparison and combination of blood DNA methylation at smoking-associated genes and at lung cancer-related genes in prediction of lung cancer mortality.

Zhang Y, Breitling LP, Balavarca Y, Holleczek B, Schöttker B, Brenner H.

Int J Cancer. 2016 Dec 1;139(11):2482-92. doi: 10.1002/ijc.30374. Epub 2016 Aug 22.

46.

Epigenetic age acceleration predicts cancer, cardiovascular, and all-cause mortality in a German case cohort.

Perna L, Zhang Y, Mons U, Holleczek B, Saum KU, Brenner H.

Clin Epigenetics. 2016 Jun 3;8:64. doi: 10.1186/s13148-016-0228-z. eCollection 2016.

47.

Comparison of prostate cancer survival in Germany and the USA: can differences be attributed to differences in stage distributions?

Winter A, Sirri E, Jansen L, Wawroschek F, Kieschke J, Castro FA, Krilaviciute A, Holleczek B, Emrich K, Waldmann A, Brenner H; Association of Population-based Cancer Registries in Germany (GEKID) Cancer Survival Working Group.

BJU Int. 2017 Apr;119(4):550-559. doi: 10.1111/bju.13537. Epub 2016 Jun 20.

48.

Histologic types of gastric cancer among migrants from the former Soviet Union and the general population in Germany: what kind of prevention do we need?

Jaehn P, Holleczek B, Becher H, Winkler V.

Eur J Gastroenterol Hepatol. 2016 Aug;28(8):863-70. doi: 10.1097/MEG.0000000000000645.

PMID:
27187801
49.

Survival of elderly patients with multiple myeloma-Effect of upfront autologous stem cell transplantation.

Merz M, Jansen L, Castro FA, Hillengass J, Salwender H, Weisel K, Scheid C, Luttmann S, Emrich K, Holleczek B, Katalinic A, Nennecke A, Straka C, Langer C, Engelhardt M, Einsele H, Kröger N, Beelen D, Dreger P, Brenner H, Goldschmidt H; GEKID Cancer Survival Working Group and the DRST.

Eur J Cancer. 2016 Jul;62:1-8. doi: 10.1016/j.ejca.2016.04.004. Epub 2016 May 10.

PMID:
27185572
50.

Survival in patients with acute myeloblastic leukemia in Germany and the United States: Major differences in survival in young adults.

Pulte D, Jansen L, Castro FA, Krilaviciute A, Katalinic A, Barnes B, Ressing M, Holleczek B, Luttmann S, Brenner H; GEKID Cancer Survival Working Group.

Int J Cancer. 2016 Sep 15;139(6):1289-96. doi: 10.1002/ijc.30186. Epub 2016 May 31.

Supplemental Content

Loading ...
Support Center